Pain Outcomes Associated With Exogenous Hormone Therapy in Adults

TRANSPIRE is an observational study of \~200 individuals who (1) will be initiating gender-affirming hormone therapy (GHT) or (2) are gender minority individuals who do not use GHT. The primary outcome will be to identify how the presence of chronic pain changes overtime with GHT through the use of surveys, quantitative sensory testing (QST), brain MRIs, and qualitative interviews. Following recruitment and consent, participants will complete baseline survey measures and will repeat those measures at 1 months, 3 month, 6 months, and 12 months. QST measures, brain MRIs, and Qualitative Interviews will be offered to participants in cohort (1) and will be completed at baseline and 12 months.

NCT Number	NCT06939257
Lead Sponsor	University of Kansas Medical Center Collaborators: National Institute of Neurological Disorders and Stroke (NINDS)
Conditions	Pain, Gender Minority Individuals
Enrollment	200 participants
Start Date	2025-03-31
Primary Completion	2029-09-16 (estimated)
Study Completion	2029-09-16 (estimated)
Updated on ClinicalTrials.gov	2026-05-14